Humacyte’s (HUMA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report released on Friday,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other analysts also recently weighed in on the stock. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average price target of $13.43.

Humacyte Trading Up 34.1 %

NASDAQ:HUMA opened at $4.64 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97. The firm has a market capitalization of $583.99 million, a price-to-earnings ratio of -3.46 and a beta of 1.38. The business’s 50-day moving average price is $4.83 and its two-hundred day moving average price is $5.85.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 in the last 90 days. 11.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Large investors have recently modified their holdings of the business. State Street Corp raised its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares during the last quarter. Millennium Management LLC raised its stake in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Humacyte by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after buying an additional 66,946 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.